New England Journal of Medicine
Author:
Keywords:
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Disease-Free Survival, Female, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Male, Melanoma, Middle Aged, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Young Adult, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, MUTATIONS, PATHWAY, CANCER, KINASE, RESISTANCE, CRITERIA, METRIC Study Group, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences
Abstract:
Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population.